Skip to main content
. 2022 Nov 16;13:1030800. doi: 10.3389/fphar.2022.1030800

FIGURE 2.

FIGURE 2

EP4 inhibition aggravates AKI-to-CKD transition. (A,B) Representative micrographs of HE and Masson staining of kidney sections from sham and IRI-induced AKI mice injected with control or EP4 inhibitor ONO-AE3-208. (C) Scoring of injury score and fibrotic area according to HE and Masson staining of kidney sections from sham and IRI mice. (D) Serum creatinine and blood urea nitrogen levels of sham and IRI mice. (E) The mRNA levels of Kim-1 and Ngal in the kidney of sham and IRI mice analyzed by qPCR. (F) Representative Immunostaining of fibronectin and α-SMA in kidney sections from sham and IRI mice. (G) Western blot analysis for fibronectin and α-SMA protein levels in kidney sections from sham and IRI mice. (H) Flow cytometric analysis of the percentage of EP4, M1 (CD86+) and M2 (CD163+) in renal macrophages (Zombie−CD45+CD11b+F4/80+cells) in kidney of sham and IRI mice. (I) Western blot analysis for EP4 protein levels in kidney sections from sham and IRI mice treated with ONO-AE3-208. Scale bars, 50 μm. n = 6 mice per group. Data are means ± s.d. ***p < 0.001, **p < 0.01, *p < 0.05.